Conference Coverage

VIDEO: Switch ANCA-associated vasculitis patients to maintenance therapy after 6 months


 

AT THE ANNUAL PERSPECTIVES IN RHEUMATIC DISEASES

References

LAS VEGAS – After 3-6 months of remission induction therapy with high-dose steroids and cyclophosphamide, it’s time to switch ANCA-associated vasculitis patients to maintenance therapy.

Recent studies have shown it’s not necessary to go beyond that point with induction treatment; patients do well by then with less toxic maintenance agents.

Dr. Brian Mandell explained how he and his colleagues at the Cleveland Clinic handle the matter and what they use for maintenance therapy, at the conference held by Global Academy for Medical Education. Global Academy for Medical Education and this news organization are owned by Frontline Medical Communications.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

aotto@frontlinemedcom.com

Recommended Reading

Think methotrexate for juvenile localized scleroderma
MDedge Rheumatology
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
MDedge Rheumatology
Maintenance therapy options for childhood alopecia areata
MDedge Rheumatology
Check thyroid function in children with vitiligo
MDedge Rheumatology
Whole exome sequencing finds TREX1 mutation in a child with cerebral lupus
MDedge Rheumatology
Neuronal autoantibodies may contribute to hippocampal atrophy in SLE, Sjögren’s
MDedge Rheumatology
Juvenile facial linear scleroderma is a neurocutaneous disease
MDedge Rheumatology
Lupus severity and genotype associated with greater risk of pneumonia
MDedge Rheumatology
Prolonged remission in systemic lupus erythematosus rare but more likely in milder disease
MDedge Rheumatology
VIDEO: Screen scleroderma patients annually for pulmonary hypertension
MDedge Rheumatology